LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Study Details
Study Description
Brief Summary
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Detailed Description
Remission Induction:
-
Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8
-
Daunorubicin (DNR): 60 mg/m2 i.v., days 1 and 8.
-
Prednisone (PDN): 60 mg/m2/day, i.v. or p.o., days 1 to 14
-
L-asparaginase (L-ASA): 10.000 UI/m2, i.v.days 5-7 and 11-13
Results:
- Standard response: The induction treatment will be completed with the same drugs, changing L-ASA to ARA-C, during two more weeks
2 Slow response. Chemotherapy with mitoxantrone and high dose ARA-C
Intrathecal chemotherapy:
Treatment with mitoxantrone, ARA-C e hydrocortisone, days 1 and 22
CONSOLIDATION TREATMENT 1
Start in two weeks after last dose of induction chemotherapy:
-
Mercaptopurine (MP) 50 mg/m2, p.o., days 1-7, 28-35 and 56-63
-
Mitoxantrone (MTX): 3g/m2, i.v., in 24 hours, day 1, 28 and 56.
-
VM-26: 150 mg/m2 every 12 horas, i.v. (infusión 1 hora), días 14 y 42
-
ARA-C: 500 mg/m2 cada 12 hours, i.v., in 3 hours, days 14-15 and 42-43
-
Intrathecal treatment, days 28 and 56.
6.4. CONSOLIDATION TREATMENT 2
Start in a week after last dose of mercaptopurine of previous cycle
-
Dexamethasone (DXM):
-
10 mg/m2 day, p.o. or i.v. days 1-14
-
5 mg/m2 day, p.o. or i.v., days 15-21
-
Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8 and 15
-
Daunorubicin (DNR): 30 mg/m2 i.v., days 1, 2, 8 and 9.
-
CFM 600 mg/m2 day, i.v., days 1 and 15
-
L-asparaginase (L-ASA): 10.000 UI/m2, i.v.or im , days 1-3 and 15-17
-
Intrathecal treatment days 1 and 15.
TRANSPLANTATION
Hematopoietic autologous transplantation with related donor, one or two months after last dose of consolidation treatment.
Hematopoietic autologous transplantation with unrelated donor, in patients younger than 45, and with PS 0-1
Hematopoietic autologous transplantation in patients without related donor and without unrelated donor after six months searching
Study Design
Outcome Measures
Primary Outcome Measures
- To evaluate the efficacy of treatment in order to response rate, relapse free survival and overall survival [5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
ALL BCR/ABL+ patients Age < 65 years No previous treatment
Exclusion Criteria:
-
Other LLA variability
-
Previous history of coronary valvular, hypertensive cardiopathy illness
-
Chronic hepatic illness
-
Chronic respiratory insufficiency
-
Renal insufficiency not caused by LLA
-
Severe neurological problems not caused by LLA
-
Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hospital Central de Asturias | Oviedo | Asturias | Spain | |
2 | Hospital general de Castellón | Castello | Castellón | Spain | |
3 | Hospital de Navarra | Pamplona | Navarra | Spain | |
4 | Hospital Verge de la Cinta | Tortosa | Tarragona | Spain | |
5 | Complejo Hospitalario Universitario de Albacete | Albacete | Spain | ||
6 | Hospital General de Alicante | Alicante | Spain | ||
7 | Hospital Ntra. Sra. Sonsoles | Avila | Spain | ||
8 | Hospital de Badalona Germans Trias i Pujol | Badalona | Spain | ||
9 | Hospital Clínic | Barcelona | Spain | ||
10 | Hospital de Sant Pau | Barcelona | Spain | ||
11 | Hospital del Mar | Barcelona | Spain | ||
12 | Hospital vall d'Hebrón | Barcelona | Spain | ||
13 | Basurtuko Ospitalea | Basurto | Spain | ||
14 | Hospital de Cruces | Bilbao | Spain | ||
15 | Hospital de Jerez de la Frontera | Jerez de La Frontera | Spain | ||
16 | Complejo Hospitalario León | Leon | Spain | ||
17 | Hospital Arnau de Vilanova | Lleida | Spain | ||
18 | Complexo Hospitalario Xeral-Calde | Lugo | Spain | ||
19 | Clínica Puerta de Hierro | Madrid | Spain | ||
20 | Hospital 12 de Octubre | Madrid | Spain | ||
21 | Hospital Clínico San Carlos de Madrid | Madrid | Spain | ||
22 | Hospital de la Princesa | Madrid | Spain | ||
23 | Hospital General Universitario Gregorio Marañón, Madrid | Madrid | Spain | ||
24 | Hospital Universitario de la Princesa | Madrid | Spain | ||
25 | Althaia, Xarxa Asistencial de Manresa | Manresa | Spain | ||
26 | Hospital General Morales Meseguer | Murcia | Spain | ||
27 | Hospital General Universitario Morales Meseguer. | Murcia | Spain | ||
28 | Hospital Santa María del Rosell | Murcia | Spain | ||
29 | . Hospital Clínico Universitario Virgen de la Victoria | Málaga | Spain | ||
30 | H. Carlos Haya | Málaga | Spain | ||
31 | Complejo Asistencial Son Dureta | Palma de Mallorca | Spain | ||
32 | Hospital Son Llatzer | Palma de Mallorca | Spain | ||
33 | Clínica Universitaria de Navarra | Pamplona | Spain | ||
34 | Complejo Hospitalario de Pontevedra_Hospital Montecelo | Pontevedra | Spain | ||
35 | Corporació Sanitaria Parc Taulí | Sabadell | Spain | ||
36 | Hospital de Sagunto | Sagunto | Spain | ||
37 | Hospital Clínico Universitario de Salamanca | Salamanca | Spain | ||
38 | Complejo Hospitalario Universitario de Santiago | Santiago de Compostela | Spain | ||
39 | Hospital General de Segovia | Segovia | Spain | ||
40 | H.U. Virgen del Rocio | Sevilla | Spain | ||
41 | Hospital Universitario de Canarias | Tenerife | Spain | ||
42 | Hospital Clínico Universitario de Valencia | Valencia | Spain | ||
43 | Hospital Clínic | Valencia | Spain | ||
44 | Hospital dr. Peset | Valencia | Spain | ||
45 | Hospital General Universitario | Valencia | Spain | ||
46 | Hospital La Fe | Valencia | Spain | ||
47 | Hospital Clínico de Valladolid | Valladolid | Spain | ||
48 | Complejo Hospitalario Universitario de Vigo | Vigo | Spain | ||
49 | Hospital de Galdakao | Vizcaya | Spain | ||
50 | Hospital Clínico Lozano Blesa | Zaragoza | Spain |
Sponsors and Collaborators
- PETHEMA Foundation
Investigators
- Study Chair: Ribera Josep Mª, Dr, Germans Trias i Pujol Hospital
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- LAL-Ph-2000